Earnings ConcernsInvestor confidence might be shaken as the company's EBITDA missed estimates because of non-cash impairment charges, negatively impacting the bottom line.
Forecast AdjustmentsThe company's future growth prospects could be questioned as analysts have lowered revenue and EBITDA forecasts, awaiting results from the Phase 2 Autism trial.
Regulatory RisksThe stock may face volatility as the company's Phase 3 clinical trial is subject to clinical and FDA approval risks.